Skip to main content

Table 4 HIV- and obstetric-related parameters, stratified according to antiretroviral third agent class

From: An observational study of initial HIV RNA decay following initiation of combination antiretroviral treatment during pregnancy

  PI
n = 132
NNRTI
n = 32
INSTI
n = 17
ABC/3TC/AZT
n =11
p-values (with Bonferroni correction)
HIV RNA half-life decay, days 2.6 (1.6–11.5) 2.3 (1.4–5.3) 1.8 (1.1–6.0) 2.6 (1.8–10.3) χ2(3) = 30.92, p < 0.001
PI vs NNRTI, p = 0.03
PI vs INSTI, p < 0.001
PI vs ABC/3TC/AZT, p = 0.87
NNRTI vs INSTI, p < 0.001
NNRTI vs ABC/3TC/AZT, p = 0.32
INSTI vs ABC/3TC/AZT, p = 0.03
Baseline pVL, log10 copies/mL 4.2 (2.5–5.8) 4.3 (2.8–5.4) 5.0 (4.0–5.8) 3.8 (2.9–4.5) χ2(3) = 28.14, p < 0.001
PI vs NNRTI, p = 0.13
PI vs INSTI, p < 0.001
PI vs ABC/3TC/AZT, p = 0.04
NNRTI vs INSTI, p = 0.18
NNRTI vs ABC/3TC/AZT, p = 0.03
INSTI vs ABC/3TC/AZT, p < 0.001
Baseline CD4+ T-cell count, cells/µL 359 (63–1136) 207 (30–848) 215 (10–700) 574 (290–1008) χ2(3) = 31.20, p < 0.001
PI vs NNRTI, p < 0.001
PI vs INSTI, p = 0.28
PI vs ABC/3TC/AZT, p = 0.03
NNRTI vs INSTI, p = 0.56
NNRTI vs ABC/3TC/AZT, p < 0.001
INSTI vs ABC/3TC/AZT, p = 0.06
Gestational age when cART was started, weeks 21.2 (5.7–39.6) 18.9 (4.9–34.0) 17.6 (8.1–34.4) 21.9 (10.9–24.0) χ2(3) = 3.67, p = 0.299
pVL 14 days after cART was initiated, log10 HIV RNA copies/mL 2.5 (1.5–4.1) 2.5 (1.8–3.6) 2.4 (1.5–4.3) 1.9 (1.7–2.9) χ2(3) = 6.94, p = 0.074
Time taken to reach pVL < 50 copies/mL, daysa 51.5 (7–174) 51.5 (21–188) 27.5 (6–121) 32.5 (21–63) χ2(3) = 12.99, p = 0.005
PI vs NNRTI, p = 0.63
PI vs INSTI, p = 0.09
PI vs ABC/3TC/AZT, p = 0.07
NNRTI vs INSTI, p = 0.05
NNRTI vs ABC/3TC/AZT, p = 0.35
INSTI vs ABC/3TC/AZT, p = 0.45
Women with pVL < 50 copies/mL at 36 weeks’ gestation 95 (72.0) 21 (65.6) 13 (76.5) 11 (100) p = 0.13
Women with pVL < 50 copies/mL at delivery 113 (85.6) 24 (75.0) 16 (94.1) 11 (100) p = 0.17
Values are median (range) or total (%)      
  1. PI protease inhibitor, NNRTI non-nucleoside reverse transcriptase inhibitor, INSTI integrase strand transferase inhibitor, ABC abacavir, 3TC lamivudine, AZT zidovudine, cART combination antiretroviral treatment, pVL plasma viral load
  2. aOnly women who achieved plasma viral loads lower than the limits of quantification prior to delivery are included
\